TFDA Taiwan Medical Device Registration

Medical devices and in vitro diagnostics in Taiwan are regulated by the Taiwan Food and Drug Administration (TFDA) under the Ministry of Health and Welfare. The Medical Devices Act provides the central legal framework. TFDA maintains current rules and guidance on its official medical devices page.

Taiwan medical device classification

Taiwan uses Classes 1, 2, and 3, from lower to higher risk. Classification is based on the intended use and product characteristics and is assigned against Taiwan's classification regulations and product categories. A US, EU, or other overseas class can inform the analysis but does not determine the Taiwan result.

Lower-risk Class 1 products may follow a listing route, while Class 2 and Class 3 products generally require registration and a fuller technical review. The exact pathway, evidence, and whether a simplified route applies depend on the product category, prior approvals, and current TFDA rules. IVDs should be assessed under the classifications and requirements applicable to their intended testing purpose.

Local license holder and QMS review

A foreign manufacturer generally needs a Taiwan-based medical device business to act as the local license holder and regulatory contact. The agreement should cover dossier access, authority responses, change reporting, license maintenance, complaints, vigilance, recalls, and transfer arrangements.

Quality-system compliance is a separate workstream from the product application. Depending on the device and manufacturing activities, the manufacturer may need TFDA quality-management-system documentation review, often referred to in practice as QMS or historically QSD review. Exemptions or simplified evidence for particular lower-risk products should be confirmed rather than assumed.

Technical file and lifecycle

A registration file commonly includes intended use, classification, device descriptions, manufacturer and site information, authorization documents, labeling and instructions for use, quality-system evidence, risk management, verification and validation, and clinical or performance evidence proportionate to risk. Chinese labeling and the local license-holder details must match the approved product.

After listing or registration, the manufacturer and license holder must keep product, site, quality certificates, and label information current. Complaints, adverse events, field safety corrective actions, and recalls need coordinated procedures. Design, software, intended-use, site, or labeling changes should be assessed before implementation to determine whether TFDA notification, approval, or a new application is required.

Taiwan pathway and evidence decisions

A product licence and manufacturing quality-system review are different records. Do not present a commercial ISO 13485 certificate as the same thing as TFDA QMS acceptance, or claim one exemption for every nonsterile Class 1 device without checking the applicable activities and rules.

Use the official TFDA instructions and related official process guidance for the filing scope. Maintain a controlled record of the chosen route, current evidence, open gaps, responsible parties and authority responses. Separate fees, document preparation, review and applicant work when planning the launch.

For a multi-country program, use the market directory to coordinate evidence reuse while retaining the local applicant, language, registration and postmarket requirements for each destination.